Quick Answer
Lineage Cell Therapeutics, Inc. reported Net Income of -$63.53 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$63.53M | -241.4% |
| 2024 | -$18.61M | +13.4% |
| 2023 | -$21.49M | +18.2% |
| 2022 | -$26.27M | +38.9% |
| 2021 | -$43.02M | -108.3% |
| 2020 | -$20.65M | -76.4% |
| 2019 | -$11.71M | +74.5% |
| 2018 | -$45.99M | -130.2% |
| 2017 | -$19.98M | -159.5% |
| 2016 | $33.57M | +171.4% |
| 2015 | -$46.99M | -29.1% |
| 2014 | -$36.41M | +17.0% |
| 2013 | -$43.88M | -104.8% |
| 2012 | -$21.43M | -29.7% |
| 2011 | -$16.52M | -47.7% |
| 2010 | -$11.18M | -117.4% |
| 2009 | -$5.14M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$29.78M | -881.6% | +2.2% |
| June 30, 2025 | -$30.46M | -428.9% | -636.0% |
| March 31, 2025 | -$4.14M | +36.7% | -36.4% |
| September 30, 2024 | -$3.03M | +57.3% | +47.3% |
| June 30, 2024 | -$5.76M | -10.2% | +12.0% |
| March 31, 2024 | -$6.54M | -49.6% | +8.0% |
| September 30, 2023 | -$7.11M | -17.2% | -36.0% |
| June 30, 2023 | -$5.23M | +22.7% | -19.6% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -241.4% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, Lineage Cell Therapeutics, Inc.’s net income has declined by 1135.0% (from -$5.14 million to -$63.53 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: